An annual injection to prevent HIV infection is closer to becoming reality after the first stage of a drug trial showed promising results.

COVID-19 took the lives of more than one million Americans and nearly 116,000 Californians, according to the Centers for Disease Control and Prevention.

HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an ...

After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Research on the presence of thyroid abnormalities in HIV showed that patients with HIV are at risk for developing a variety of thyroid disorders.

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

Without public health surveillance, officials trying to tackle outbreaks, identify threats and evaluate treatments are working ‘in the darkness of ignorance.’ ...

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks ...